Last reviewed · How we verify
GZR-33
At a glance
| Generic name | GZR-33 |
|---|---|
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State (PHASE1)
- A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD (PHASE2)
- A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects (PHASE1)
- A Clinical Study of GZR33 and GZR101 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GZR-33 CI brief — competitive landscape report
- GZR-33 updates RSS · CI watch RSS
- Gan and Lee Pharmaceuticals, USA portfolio CI